

Date: 11/11/2016

To

Deputy Manager
Dept. of Corporate Services,
Bombay Stock Exchange Limited
P J Towers, Dalal Street,
Fort, MUMBAI - 400001

Dear Sir/Madam,

Sub: Unaudited financial results for the quarter and half year ended on
30th September, 2016

Ref: Reg. 33 of SEBI(Listing obligations and Disclosure Requirements)

Regulations, 2015 Agreement, Script Code# 511509

With reference to subject cited above please find enclosed Unaudited financial results for the quarter and half year ended on 30th September, 2016 as per the Reg.33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 along with Limited Review Report issued by the Statutory Auditors of the company

This is for your record and reference.

Thanking you,

Yours faithfully,

For Vivo Bio Tech Limited

M Kalyan Ram
M Kalyan Ram
Whole Time Director
DIN: 02012580



Notes:

1. The above financial results are recommended by the Audit Committee were considered and approved by the board of directors at their meeting held on 11th November, 2016.
2. In accordance with the Regulation 33 of the SEBI((Listing and Other Disclosure Requirements) Regulations, 2015, Statutory Auditors have performed limited review of the financial results of M/s. Vivo Bio Tech Limited for the quarter and half year ended 30th September, 2016. There are no qualifications in the limited review report issued for the said period
3. The Entire operations of the company relate to single segment viz., Bio Technology. Hence Segmental reporting as per AS-17 is not made.
4. Previous year's/period's figures are rearranged/ regrouped wherever necessary

Date: 11th November, 2016
Place: Hyderabad

For Vivo Bio Tech Limited

M Kalyan Ram
M Kalyan Ram
Whole Time Director
DIN: 02012580



Statement of Unaudited Financial Results for the quarter and Half year ended on 30th September, 2016		QUARTER ENDED			HALF YEAR ENDED			YEAR ENDED	
		30-Sep-16	30-Jun-16	30-Sep-15	30-Sep-16	30-Sep-15	30-Sep-15	31-Mar-16	
S.No.	PARTICULARS	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1	Income from Operations	891.85	623.32	726.61	1,515.17	1,331.83	2,851.90		
	a) Net Sales/ Income from Operations	-	194.87	-	194.87	-	6.43		
	b) Other Operating Income	891.85	818.19	726.61	1,710.04	1,331.83	2,858.33		
2	Total Income from operations								
	Expenses								
	a. Increase/decrease in stock in trade and WIP	(81.59)	122.40	(79.77)	40.81	(79.77)	60.56		
	b. Consumption of Raw materials	200.92	205.00	228.10	405.92	418.18	819.29		
	c. Purchase of traded goods	-	-	-	-	-	-		
	d. Employees Cost	137.15	131.68	110.84	268.83	198.92	434.26		
	e. Depreciation	96.80	83.85	91.39	180.65	167.55	335.40		
	f. Other Expenditure	-	-	-	-	-	-		
	1. Administrative Expenditure	401.92	237.61	366.26	639.53	577.05	1,173.46		
	g. Total	755.20	780.54	716.83	1,535.74	1,281.94	2,822.97		
3	Profit/loss from Operations before other income, finance cost and exceptions items(L-2)	136.65	37.65	9.78	174.30	49.89	35.36		
4	Other income	12.58	23.37	26.46	35.95	44.35	89.25		
5	Profit/(loss) from Ordinary activities before finance costs and exceptional items(3+4)	149.22	61.02	36.25	210.24	94.24	124.61		
6	Finance costs	8.70	9.63	11.53	18.33	21.13	46.57		
7	Profit/(loss) from Ordinary activities after finance costs but before exceptional items(5-6)	140.52	51.39	24.72	191.91	73.11	78.04		
8	Exceptional items	-	-	-	-	-	-		
9	Profit/Loss from Ordinary Activities before tax(7-8)	140.52	51.39	24.72	191.91	73.11	78.04		
10	Tax Expense	25.02	11.31	7.41	36.33	21.93	(12.96)		
11	Net Profit/Loss from Ordinary Activities after Tax(9-10)	115.50	40.08	17.30	155.58	51.18	91.00		
12	Extraordinary Items (Net of Tax expense of Rs.....Lakh)	-	-	-	-	-	-		
13	Net Profit/Loss for the Period(11-12)	115.50	40.08	17.30	155.58	51.18	91.00		
14	Paid Up Share Capital(Face Value of Rs.10/-each)	935.05	935.05	935.05	935.05	935.05	935.05		
15	Reserves Excluding Revaluation Reserves as per Balance sheet of previous accounting year	-	-	-	-	-	-		
16.i	Earning Per Share(EPS)(Before Extraordinary items)								
	a) Basic	1.24	0.43	0.19	1.66	0.55	0.97		
	b) Diluted	1.24	0.43	0.19	1.66	0.55	0.97		
16.ii	Earning Per Share(EPS)(After Extraordinary items)								
	a) Basic	1.24	0.43	0.19	1.66	0.55	0.97		
	b) Diluted	1.24	0.43	0.19	1.66	0.55	0.97		

For Vivo Bio Tech Limited

M. Kalpan Ram
Whole Time Director
DIN : 02012580

Place: Hyderabad
Date: 11th November 2016



Statement of Assets and Liabilities			
Particulars	AS AT 30/09/2016		As AT 31/03/2016
		Unaudited	Audited
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	a) Share Capital	9,35,05,200	9,35,05,200
	b) Reserves and Surplus	2,28,83,908	73,25,870
	Sub-total -Shareholders' Funds	11,63,89,108	10,08,31,070
2	Non-Current Liabilities		
	a) Long Term borrowings	1,98,92,877	2,33,93,315
	b) Deffered tax liabilities	83,81,360	84,05,859
	c) Other Long term liabilities	-	-
	d) Long term provisions	22,80,788	20,30,215
	Sub-total -Non-Current Liabilities	3,05,55,025	3,38,29,389
3	Current Liabilities		
	a) Short-term Borrowings	2,64,03,233	2,80,50,004
	b) Trade Payables	3,26,81,245	8,74,63,132
	c) Other Curren Liabilities	20,35,21,334	19,48,80,981
	d) Short Term provisions	1,47,62,458	1,16,60,578
	Sub-total -Current Liabilities	27,73,68,269	32,20,54,695
	TOTAL-EQUITY AND LIABILITIES	42,43,12,403	45,67,15,154
B	ASSETS		
1	Non-Current Assets		
	a) Fixed Assets		
	i) Tangible Assets	16,80,04,739	16,94,23,714
	ii) Intangible Assets	5,97,54,525	6,40,79,664
	(iii) Capital Work-in-progress	4,29,08,679	4,19,482
	b) Non-Current Investments	3,00,000	3,00,000
	e) Other non-current assets	5,14,517	3,60,337
	Sub-total Non-Current Assets	27,14,82,460	23,45,83,197
2	Current Assets		
	a) Inventories	3,67,32,623	4,08,14,026
	b) Trade Receivables	3,59,04,227	3,81,90,757
	c) Cash and cash equivalents	5,57,37,356	11,85,11,094
	d) short term loans and advances	97,79,416	86,20,533
	e) Other current assets	1,46,76,321	1,59,95,547
	Sub-Total Current Assets	15,28,29,944	22,21,31,956
	TOTAL ASSETS	42,43,12,403	45,67,15,153

Place: Hyderabad
Date: 11th November 2016

For Vivo Bio Tech Limited

M Kalyan Ram
M Kalyan Ram
Whole Time Director
DIN : 02012580



Registered Office : #608, 6th Floor, Lingapur, Himayath Nagar, Hyderabad - 500 029. T.S. INDIA.

Address of Preclinical Research Facility : Sy. # 349/A, Pregnapur - 502 311, Gajwel Mandal, Medak District. T.S. INDIA.

Phone : +91-40-27890662-5, Fax : +91-40-27890669. website : www.vivobio.com

CIN : L65993TG1987PLC007163



P. MURALI & CO.,

CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470

Fax : (91-40) 2339 2474

E-mail : pmurali.co@gmail.com
info@pmurali.com

Website : www.pmurali.com


To
The Board of Directors
VIVO BIO TECH LIMITED
Hyderabad

Limited Review Report for Standalone Financials for the quarter ended 30th September, 2016

1. We have reviewed the accompanying statement of unaudited Standalone financial results of M/s. Vivo Bio Tech Limited for the quarter ended 30th September, 2016, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015.
2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors in their meeting held on 11th November, 2016. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of interim financial information performed by the independent auditor of the entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure requirements) Regulations, 2015 and SEBI circular dated 05th July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.
Chartered Accountants
FRN: 007257S

A Krishna Rao
Partner
M.No. 020085



Place: Hyderabad
Date: 11th November, 2016